Biotech by today's price change
How far the share price has moved since the previous close.
Repligen leads the 24 biotech ranked by today's price change, at +4.87%, ahead of CRISPR Therapeutics (+4.60%) and Scholar Rock Holding (+3.39%). Figures as of 18 Nov 2026, 14:43 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Repligen+4.87%
- Median
- +0.30%
- Combined market value
- SAR 3.18T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Today ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | RepligenRGEN · Health Care | +4.87% | SAR 40.8B | SAR 637.99 | 4.87% up | 5% up | ||
| 2 | CRISPR TherapeuticsCRSP · Health Care | +4.60% | SAR 15.3B | SAR 157.53 | 4.60% up | 21% down | ||
| 3 | Scholar Rock HoldingSRRK · Health Care | +3.39% | SAR 21.3B | SAR 174.83 | 3.39% up | 14% up | ||
| 4 | argenxARGX · Health Care | +1.34% | SAR 226.5B | SAR 3,601.67 | 1.34% up | 4% up | ||
| 5 | Krystal BiotechKRYS · Health Care | +1.31% | SAR 33.6B | SAR 1,134.49 | 1.31% up | 46% up | ||
| 6 | Twist BioscienceTWST · Health Care | +1.18% | SAR 29B | SAR 425.06 | 1.18% up | 340% up | ||
| 7 | Kymera TherapeuticsKYMR · Health Care | +1.03% | SAR 39.3B | SAR 460.51 | 1.03% up | 87% up | ||
| 8 | Adaptive BiotechnologiesADPT · Health Care | +0.95% | SAR 17.5B | SAR 107.88 | 0.95% up | 88% up | ||
| 9 | ImmunovantIMVT · Health Care | +0.93% | SAR 26B | SAR 125.73 | 0.93% up | 43% up | ||
| 10 | CG OncologyCGON · Health Care | +0.56% | SAR 26.6B | SAR 297.75 | 0.56% up | 85% up | ||
| 11 | BiogenBIIB · Health Care | +0.41% | SAR 139.6B | SAR 944.58 | 0.41% up | 49% up | ||
| 12 | BioNTechBNTX · Health Care | +0.30% | SAR 79.2B | SAR 319.27 | 0.30% up | 16% down | ||
| 13 | ModernaMRNA · Health Care | +0.30% | SAR 314.8B | SAR 778.03 | 0.30% up | 755% up | ||
| 14 | Halozyme TherapeuticsHALO · Health Care | +0.27% | SAR 41.2B | SAR 360.94 | 0.27% up | 37% up | ||
| 15 | Bio-TechneTECH · Health Care | +0.13% | SAR 42.9B | SAR 272.79 | 0.13% up | 26% up | ||
| 16 | ExelixisEXEL · Health Care | +0.11% | SAR 62.8B | SAR 257.22 | 0.11% up | 63% up | ||
| 17 | QiagenQGEN · Health Care | -0.06% | SAR 38.5B | SAR 186.50 | 0.06% down | 12% up | ||
| 18 | Neurocrine BiosciencesNBIX · Health Care | -0.19% | SAR 62.9B | SAR 621.17 | 0.19% down | 20% up | ||
| 19 | VaxcytePCVX · Health Care | -0.29% | SAR 35.2B | SAR 222.15 | 0.29% down | 22% up | ||
| 20 | Gilead SciencesGILD · Health Care | -0.34% | SAR 789.4B | SAR 636.47 | 0.34% down | 33% up | ||
| 21 | Kodiak SciencesKOD · Health Care | -0.39% | SAR 23.7B | SAR 361.67 | 0.39% down | 396% up | ||
| 22 | ImmunityBioIBRX · Health Care | -0.64% | SAR 24.8B | SAR 23.33 | 0.64% down | 193% up | ||
| 23 | Revolution MedicinesRVMD · Health Care | -0.74% | SAR 131B | SAR 605.73 | 0.74% down | 131% up | ||
| 24 | AmgenAMGN · Health Care | -1.10% | SAR 918.9B | SAR 1,698.75 | 1.10% down | 34% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7510 SAR).
Questions and answers
Which biotech rank first by today's price change?
Repligen (+4.87%), CRISPR Therapeutics (+4.60%) and Scholar Rock Holding (+3.39%) are the top three of the 24 biotech ranked by today's price change as of 18 Nov 2026, 14:43 UTC.
How many biotech are in this ranking?
24 are ranked by today's price change.
What are these biotech worth together?
The 24 biotech ranked by today's price change have a combined market value of SAR 3.18T as of 18 Nov 2026, 14:43 UTC.
What does ranking by today's price change measure?
How far the share price has moved since the previous close.
Learn how this ranking works
All markets guides →- 52-week high and low: what the range tells you
A stock's 52-week high and low are the highest and lowest prices it reached over the past year. Where today's price sits in that range, from 0% at the low to 100% at the high, shows how the past year has gone. Sources differ on whether they use closing or intraday prices, so the same stock's range can differ slightly.
- Drawdown and recovery: why a 50% fall needs a 100% gain
A drawdown is how far a price has fallen from its previous peak, as a percentage of that peak. Recovery needs a larger gain than the fall, because the gain starts from a smaller base: a 20% drop needs a 25% rise to get back, a 50% drop needs 100%, and a 75% drop needs 300%.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Biotech by today's price change”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=day-change
Underlying data: Yahoo Finance; SEC EDGAR.